Tianjin TEDA Biomedical Engineering Co. Ltd. (8189) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sinofert Holdings Ltd.

Cheerwin Group Ltd.

China BlueChemical Ltd.

China XLX Fertiliser Ltd.

Tianjin TEDA Biomedical Engineering Co. Ltd.

Ko Yo Chemical (Group) Ltd.

Century Sunshine Group Holdings Ltd.

Dongguang Chemical Ltd.

Why is Tianjin TEDA Biomedical Engineering Co. Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -6.24% and Operating profit at -8.63% over the last 5 years

The company declared negative results in Dec'24 after positive results in Jun'24

OPERATING CASH FLOW(Y) Lowest at HKD -42.38 MM
ROCE(HY) Lowest at -81.86%
DEBT-EQUITY RATIO (HY) Highest at 426.72 %

With ROE of 26.18%, it has a Very Expensive valuation with a 26.86 Price to Book Value

Over the past year, while the stock has generated a return of 11.11%, its profits have fallen by -77.7%

Underperformed the market in the last 1 year

The stock has generated a return of 11.11% in the last 1 year, much lower than market (Hang Seng Hong Kong) returns of 26.67%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Chemicals & Petrochemicals)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Tianjin TEDA Biomedical Engineering Co. Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Tianjin TEDA Biomedical Engineering Co. Ltd.

9.09%

4.08

72.19%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.24%

EBIT Growth (5y)

-8.63%

EBIT to Interest (avg)

5.03

Debt to EBITDA (avg)

Net Debt to Equity (avg)

3.87

Sales to Capital Employed (avg)

2.73

Tax Ratio

32.95%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

3,418.30%

ROE (avg)

1,933.92%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

103

Industry P/E

Price to Book Value

26.86

EV to EBIT

37.66

EV to EBITDA

24.70

EV to Capital Employed

6.31

EV to Sales

1.59

PEG Ratio

Dividend Yield

ROCE (Latest)

16.76%

ROE (Latest)

26.18%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Tianjin TEDA Biomedical Engineering Co. Ltd.

Cash and Eqv

Highest at HKD 69.6 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 23.73%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -195.16% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Tianjin TEDA Biomedical Engineering Co. Ltd.

Pre-Tax Profit

At HKD -32.84 MM has Fallen at -1,529.48%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -25.08 MM has Fallen at -601.72%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (HKD MM)

Operating Cash Flow

Lowest at HKD -42.38 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (HKD MM)

Net Sales

Lowest at HKD 188.66 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (HKD MM)

Operating Profit

Lowest at HKD -24.67 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (HKD MM)

Operating Profit Margin

Lowest at -13.08 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at HKD -32.84 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit

Lowest at HKD -25.08 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

EPS

Lowest at HKD -0.01

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (HKD)

Debt-Equity Ratio

Highest at 426.72 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 2.39%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio